This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cardi, G. Articles by Ernstoff, M. S. Search for Related Content PubMed PubMed Citation Articles by Cardi, G. Articles by Ernstoff, M. S.

T-Cell Receptor -Chain Expression on Tumor-infiltrating Lymphocytes from Renal Cell Carcinoma¹

The Uro-Oncology Group of the Norris Cotton Cancer Center [G. C., J. A. H., A. R. S., M. S. E.], Sections of Medical Hematology/Oncology [G. C., D. M. P., M. T. B., M. S. E.] and Urology [J. A. H.], and Department of Pathology [A. R. S.], Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756-0001; and Istituto Nazionale per la Ricerca sul Cancro di Genova Sezione di Roma, Viale Regina Elena 324, Rome, Italy [G. C.]

Loss of the T-cell receptor-associated chain in tumor-infiltrating lymphocytes (TILs) has been proposed as one mechanism of acquired immunosuppression in cancer patients. Recent reports suggest that -chain loss may be related to contaminating monocyte/macrophage protease activity. Using flow cytometry and Western blot analysis, we have confirmed the expression of chain in matched peripheral blood mononuclear cells and TILs from eight patients with primary renal cell carcinoma, when the cells were exposed to sufficient quantity of protease inhibitors. A small decrease in -chain expression was found in three TIL samples. The loss of -chain expression that was noted by others may be related to differences in laboratory method, and the small changes we have noted are unlikely to be sufficient in explaining the immunosuppression of TILs.

¹ This work was supported in part by NIH Grants CA49002 and CA23108.

² To whom requests for reprints should be addressed, at the Section of Medical Hematology/Oncology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756-0001. Phone: (603) 650-6339; Fax (603) 650-7791; E-mail: gaetano.cardi@hitchcock.org.

Received 4/24/97. Accepted 6/13/97.

This article has been cited by other articles:

				M. S. Ernstoff, T. S. Crocenzi, J. D. Seigne, N. A. Crosby, B. F. Cole, J. L. Fisher, J. C. Uhlenhake, D. Mellinger, C. Foster, C. J. Farnham, et al. Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang Clin. Cancer Res., January 15, 2007; 13(2): 733s - 740s. [Abstract] [Full Text] [PDF]

				T. Y. Shibuya, N. Nugyen, C. E. McLaren, K.-T. Li, W.-Z. Wei, S. Kim, G. H. Yoo, A. Rogowski, J. Ensley, and W. Sakr Clinical Significance of Poor CD3 Response in Head and Neck Cancer Clin. Cancer Res., March 1, 2002; 8(3): 745 - 751. [Abstract] [Full Text] [PDF]

				T. Saito, I. Kuss, G. Dworacki, W. Gooding, J. T. Johnson, and T. L. Whiteside Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1263 - 1273. [Abstract] [Full Text] [PDF]

				I. Kuss, T. Saito, J. T. Johnson, and T. L. Whiteside Clinical Significance of Decreased {{zeta}} Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer Clin. Cancer Res., February 1, 1999; 5(2): 329 - 334. [Abstract] [Full Text] [PDF]